Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Cellmid Ltd, Interim Financial Report (ASX:CDY)

The directors submit the interim consolidated financial report of Cellmid Limited and Controlled Entities ("the Consolidated Entity") for the half-year ended 31 December 2013. ...read more

Cellmid Ltd, USA RNA/DNA Patent for Surgical Adhesion Allowed (ASX:CDY)

- Patent for the treatment of surgical adhesions via midkine targeting by nucleotide based drugs allowed in the US; - Comprehensive protection over antibodies, DNA/RNA antisense and...read more

Cellmid Ltd, Chinese Distribution Agreement Signed for Hair Loss Products (ASX:CDY)

- Chinese distribution agreement signed with Beijing based company; - Cellmid’s products are expected to be sold from February 2014; - Three year exclusivity is subj...read more

Cellmid Ltd, Completed CK3000 Diagnostic Study Results (ASX:CDY)

- Largest ever study of midkine in healthy volunteers – 574 individuals; - Results are pivotal in any regulatory submission for midkine diagnostics; - Elevated midki...read more

Cellmid Ltd, AGM Presentation 2013 (ASX:CDY)

Summary - High value cancer therapeutic product pipeline going into phase 1/2a studies in solid tumors; - Revenue generating diagnostics division with multiple licenses and regu...read more

Cellmid Ltd, Newsletter - October 2013 (ASX:CDY)

Message from the CEO Since our May 2013 newsletter we have made ten material announcements to the market with strong positive impact on our diagnostic, therapeutic and consumer health businesse...read more

Cellmid Ltd, Annual Report 2013 (ASX:CDY)

REVIEW OF OPERATIONS The Group has grown its Consumer Health Business significantly during the reporting period and, with the acquisition of Advangen Inc., opened up a global opportunity for th...read more

Cellmid Ltd, Key Antibody Patent Granted in Japan (ASX:CDY)

- Japanese patent for treating autoimmune disorders using midkine antibodies granted - Novel mechanism of action boosting regulatory T cells - USA patent already granted in 20...read more

Cellmid, Key European Patent for Anti-Midkine Antibodies Granted (ASX:CDY)

- Patent for anti-midkine antibodies to prevent and treat cancer, inflammatory and autoimmune diseases granted in Europe - Most important patent family in Cellmid’s cancer tre...read more

INDEPENDENT VALUATION REPORT OF ADVANGEN INC. JAPAN (ASX:CDY)

SYDNEY, Thursday 19 September 2013: Cellmid Limited (ASX:CDY) releases an independent valuation report of Advangen Inc. Japan (Advangen Inc), a wholly owned subsidiary of Cellmid. The report has be...read more

CELLMID SIGNS MAJOR JAPANESE DISTRIBUTION AGREEMENT (ASX:CDY)

Agreement signed for the sale of 30,000 units of Cellmid’s FGF-5 inhibitor lotions Significant step in increasing Japanese sales Building strong relationship with customers with th...read more

Cellmid Ltd, Annual Financial Report - 30 June 2013 (ASX:CDY)

Review of Operations The Group has grown its Consumer Health Business significantly during the reporting period and, with the acquisition of Advangen Inc., opened up a global opportunity for th...read more

Cellmid, Pacific Edge Milestone Shares Received (ASX:CDY)

- Pacific Edge have issued 1,084,622 shares to Cellmid having achieved their requisite milestone - The shares have been issued pursuant to the midkine diagnostic license agreement s...read more

Cellmid, Collaboration on Early Diagnosis of Colorectal Cancer (ASX:CDY)

- Cellmid signed a collaboration agreement with Abcodia for testing midkine in longitudinal serum samples - Abcodia has exclusive access to a unique collection of 5,000,000 serum sa...read more

Cellmid, Notes to Appendix 4C (ASX:CDY)

SYDNEY, Friday, 26 July 2013: Cellmid Limited (ASX: CDY) provides the following comments in relation to the attached Appendix 4C form: Advangen acquisition During 4Q2013 the Company completed...read more

Viewing: 1 - 15 of 24 Previous | Next